Advances in Clinical Management of Bipolar Disorder: 2nd Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Mental Health".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 3314

Special Issue Editor


E-Mail Website
Guest Editor
2nd Department of Psychiatry, Aristotle University of Thessaloniki, 54624 Thessaloniki, Greece
Interests: psychiatric diagnostic criteria; behavioral addictions; technological addictions
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Bipolar disorder is a disabling illness due to its early onset, severity and chronicity. Its global prevalence in 2019 was estimated at nearly 40 million patients, and the disorder poses a risk for patients’ well-being, not only through direct negative outcomes but also through indirect effects associated with poverty, suicide and co-morbid health issues. Furthermore, bipolar disorder places a considerable burden on families and significant others. These facts point to the significance of appropriate therapeutic interventions for bipolar disorder. To a large extent, the first onset of the disorder will require hospitalization, with a high chance for subsequent re-entries to a clinical environment. The aim of this Special Issue is to highlight the difficulties in the clinical handling of bipolar disease and any new treatment solutions.

Dr. Georgios Floros
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bipolar disorder
  • manic episode
  • mixed episode
  • patient adherence
  • psychosocial burden
  • harm reduction

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Jump to: Other

13 pages, 418 KiB  
Review
Bipolar Disorder and Gaming Disorder—Compatible or Incompatible Diagnoses?
by Georgios Floros and Ioanna Mylona
J. Clin. Med. 2023, 12(19), 6251; https://doi.org/10.3390/jcm12196251 - 28 Sep 2023
Viewed by 1018
Abstract
Gaming Disorder (GD) is one of the latest additions in the psychiatric taxonomy, following its official inclusion in the latest revision of the International Classification of Diseases (ICD-11). This narrative review examines the rationale of an exclusion criterion for the diagnosis of GD, [...] Read more.
Gaming Disorder (GD) is one of the latest additions in the psychiatric taxonomy, following its official inclusion in the latest revision of the International Classification of Diseases (ICD-11). This narrative review examines the rationale of an exclusion criterion for the diagnosis of GD, that of disordered gaming being limited exclusively during an episode of elevated mood in bipolar disorder. The history of the formulation of diagnostic criteria for the disorder and all relevant published studies are examined critically, and conclusions are drawn as to the potential validity and usability of the exclusion criterion. Suggestions are offered for future research to elucidate not only the relevance of the exclusion criterion but also the differential diagnosis of GD with pathological gambling (PG). Full article
(This article belongs to the Special Issue Advances in Clinical Management of Bipolar Disorder: 2nd Edition)
Show Figures

Figure 1

Other

Jump to: Review

17 pages, 1299 KiB  
Systematic Review
Antimanic Efficacy, Tolerability, and Acceptability of Clonazepam: A Systematic Review and Meta-Analysis
by Andreas S. Lappas, Bartosz Helfer, Katarzyna Henke-Ciążyńska, Myrto T. Samara and Nikos Christodoulou
J. Clin. Med. 2023, 12(18), 5801; https://doi.org/10.3390/jcm12185801 - 6 Sep 2023
Cited by 1 | Viewed by 1957
Abstract
(1) Background: The use of benzodiazepines for the treatment of acute mania remains prevalent. This systematic review and meta-analysis provides an updated assessment of Clonazepam’s antimanic efficacy, tolerability, and acceptability. (2) Methods: A systematic search of multiple databases and clinical trial registries was [...] Read more.
(1) Background: The use of benzodiazepines for the treatment of acute mania remains prevalent. This systematic review and meta-analysis provides an updated assessment of Clonazepam’s antimanic efficacy, tolerability, and acceptability. (2) Methods: A systematic search of multiple databases and clinical trial registries was conducted, aiming to identify any controlled studies of Clonazepam vs. placebo or any other pharmacotherapy for the treatment of acute mania. Pairwise meta-analytic evaluations were performed. (3) Results: Six studies were included with a total number of 192 participants, all of which were randomized controlled trials. Clonazepam may be superior to a placebo in the acute phase of treatment and no different to Lithium and Haloperidol in terms of efficacy, both acutely and in the medium to long term. Clonazepam may be an acceptable and well-tolerated treatment for acute mania, especially when used as an augmentation strategy. Comparisons were underpowered, with minimal sample sizes and only one study per comparison in many cases, thus limiting the generalizability of our findings and hindering firm clinical conclusions. (4) Conclusions: Given the prevalence of benzodiazepine use in current practice, more and larger studies are urgently needed. Full article
(This article belongs to the Special Issue Advances in Clinical Management of Bipolar Disorder: 2nd Edition)
Show Figures

Graphical abstract

Back to TopTop